Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECC4703 as an Adjunct to Semaglutide in Adults With Obesity
NCT07505303Phase 2Active, not recruiting
- Sponsor
- Eccogene
- Start
- Mar 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity comparing Arm 1: ECC4703 + semaglutide with Arm 2: Placebo + semaglutide (2 arms). Primary endpoints: Percentage Change in Body Weight at Week 20, Proportion of Participants Achieving >=5% Reduction in Body Weight at Week 20 and 3 more. Started Mar 2026; status: active, not recruiting.
02
Drugs
ECC4703
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07505303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07505303.